Hickey David 4
4 · BECTON DICKINSON & CO · Filed Aug 14, 2023
Insider Transaction Report
Form 4
Hickey David
EVP & President, Life Sciences
Transactions
- Exercise/Conversion
Common Stock
2023-08-11$132.54/sh+3,883$514,653→ 9,030 total - Sale
Common Stock
2023-08-11$277.85/sh−2,974$826,326→ 4,199 total - Disposition to Issuer
Common Stock
2023-08-11$277.85/sh−1,857$515,967→ 7,173 total - Exercise/Conversion
Stock Appreciation Rights
2023-08-11−3,883→ 0 totalExercise: $132.54From: 2015-11-25Exp: 2024-11-25→ Common Stock (3,883 underlying)
Footnotes (3)
- [F1]The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $277.41 to $280.00. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder upon request.
- [F2]Award terms reflect adjustments made in connection with the spin-off of Embecta Corp.
- [F3]The stock appreciation rights vest in four annual installments beginning November 25, 2015.